tetano
Editor, Senior Moderator
Sci Rep
. 2021 Sep 28;11(1):19251.
doi: 10.1038/s41598-021-98749-4.
Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
Donato Lacedonia[SUP] 1 [/SUP], Giulia Scioscia[SUP] 1 [/SUP], Carla Santomasi[SUP] 2 [/SUP], Paolo Fuso[SUP] 1 [/SUP], Giovanna Elisiana Carpagnano[SUP] 3 [/SUP], Andrea Portacci[SUP] 3 [/SUP], Franco Mastroianni[SUP] 4 [/SUP], Giovanni Larizza[SUP] 4 [/SUP], Eugenio Sabato[SUP] 5 6 [/SUP], Emanuela Profilo[SUP] 5 [/SUP], Emanuela Resta[SUP] 7 [/SUP], Maria Pia Foschino Barbaro[SUP] 1 [/SUP], Onofrio Resta[SUP] 3 [/SUP]
Affiliations
Abstract
The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.
. 2021 Sep 28;11(1):19251.
doi: 10.1038/s41598-021-98749-4.
Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients
Donato Lacedonia[SUP] 1 [/SUP], Giulia Scioscia[SUP] 1 [/SUP], Carla Santomasi[SUP] 2 [/SUP], Paolo Fuso[SUP] 1 [/SUP], Giovanna Elisiana Carpagnano[SUP] 3 [/SUP], Andrea Portacci[SUP] 3 [/SUP], Franco Mastroianni[SUP] 4 [/SUP], Giovanni Larizza[SUP] 4 [/SUP], Eugenio Sabato[SUP] 5 6 [/SUP], Emanuela Profilo[SUP] 5 [/SUP], Emanuela Resta[SUP] 7 [/SUP], Maria Pia Foschino Barbaro[SUP] 1 [/SUP], Onofrio Resta[SUP] 3 [/SUP]
Affiliations
- PMID: 34584165
- PMCID: PMC8478875
- DOI: 10.1038/s41598-021-98749-4
Abstract
The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.